341 related articles for article (PubMed ID: 19747805)
1. A novel component of the metabolic syndrome: the oxidative stress.
Hopps E; Noto D; Caimi G; Averna MR
Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):72-7. PubMed ID: 19747805
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome.
Reaven P
J Insur Med; 2004; 36(2):132-42. PubMed ID: 15301226
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
Zarich SW
Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
[TBL] [Abstract][Full Text] [Related]
4. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
Cannon CP
Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
[TBL] [Abstract][Full Text] [Related]
5. The metabolic syndrome and its cardiovascular manifestations.
Sánchez-Torres RJ; Delgado-Osorio H
Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome.
Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage.
Mulé G; Cottone S; Nardi E; Andronico G; Cerasola G
Minerva Cardioangiol; 2006 Apr; 54(2):173-94. PubMed ID: 16778751
[TBL] [Abstract][Full Text] [Related]
8. Hepatic steatosis and vascular disease.
Santoliquido A; Di Campli C; Miele L; Gabrieli ML; Forgione A; Zocco MA; Lupascu A; Di Giorgio A; Flore R; Pola P; Gasbarrini G; Gasbarrini A; Tondi P; Grieco A
Eur Rev Med Pharmacol Sci; 2005; 9(5):269-71. PubMed ID: 16231588
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.
Otani H
Antioxid Redox Signal; 2011 Oct; 15(7):1911-26. PubMed ID: 21126197
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome: is it a syndrome? Does it matter?
Kahn R
Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
[No Abstract] [Full Text] [Related]
11. Challenges associated with metabolic syndrome.
Spinler SA
Pharmacotherapy; 2006 Dec; 26(12 Pt 2):209S-217S. PubMed ID: 17125447
[TBL] [Abstract][Full Text] [Related]
12. Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population.
Whayne TF
Indian Heart J; 2007; 59(3):218-25. PubMed ID: 19124929
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.
Dandona P; Aljada A; Chaudhuri A; Mohanty P; Garg R
Circulation; 2005 Mar; 111(11):1448-54. PubMed ID: 15781756
[No Abstract] [Full Text] [Related]
14. Metabolic risk-factor clustering estimation in children: to draw a line across pediatric metabolic syndrome.
Brambilla P; Lissau I; Flodmark CE; Moreno LA; Widhalm K; Wabitsch M; Pietrobelli A
Int J Obes (Lond); 2007 Apr; 31(4):591-600. PubMed ID: 17384660
[TBL] [Abstract][Full Text] [Related]
15. Obesity and the metabolic syndrome in the elderly--a mini-review.
Lechleitner M
Gerontology; 2008; 54(5):253-9. PubMed ID: 18841025
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
Zarich SW
Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
[TBL] [Abstract][Full Text] [Related]
17. New insights into understanding cardiometabolic risk. Introduction.
Fonarow GC; Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
[No Abstract] [Full Text] [Related]
18. Metabolic syndrome determinants in an urban population from Brazil: social class and gender-specific interaction.
Marquezine GF; Oliveira CM; Pereira AC; Krieger JE; Mill JG
Int J Cardiol; 2008 Sep; 129(2):259-65. PubMed ID: 18036678
[TBL] [Abstract][Full Text] [Related]
19. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
20. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Chapman MJ; Sposito AC
Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
